Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2293-2297

  Van Asperen, Judith ^a,c   Van Tellingen, Olaf ^a   Van Der Valk, Martin A ^a   Rozenhart, Micha ^a   Beijnen, Jos H ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CREMOPHOR; CYCLOSPORIN A; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL; POLYSORBATE 80; VALSPODAR;

ANIMAL EXPERIMENT; ARTICLE; CANCER CHEMOTHERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; P-GLYCOPROTEIN; PACLITAXEL;

EID: 0031723117     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Huizing, M. T., Sewberath Misser, V. H., Pieters, R. C., ten Bokkel Huinink, W. W., Veenhof, C. H. N., Vermorken, J. B., Pinedo, H. M., and Beijnen, J. H. Taxanes: a new class of antitumor agents. Cancer Invest., 13: 381-404, 1995.
2. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med., 332: 1004-1014, 1995.
3. Dorr, R. T. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother., 28 (Suppl.): S11-S14, 1994.
4. Theis, J. G., Liau-Chu, M., Chan, H. S., Doyle, J., Greenberg, M. L., and Koren, G. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporin for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J. Clin. Oncol., 13: 2508-2516, 1995.
5. Liu, G., Franssen, E., Fitch, M. I., and Warner, E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol., 15: 110-115, 1997.
6. Eiseman, J. L., Eddington, N. D., Leslie, J., McAuley, C., Sentz, D. L., Zuhowski, M., Kujawa, J. M., Young, D., and Egorin, M. J. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother. Pharmacol., 34: 465-471, 1994.
7. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., and van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA, 94: 2031-2035, 1997.
8. Juliano, R. L., and Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455: 152-162, 1976.
9. Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., and Pastan, I. Expression of a multidrug resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA, 84: 265-269, 1987.
10. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., and Pastan, I. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738, 1987.
11. Freeman, T. C. Parallel patterns of cell-specific gene expression during enterocyte differentiation and maturation in the small intestine of the rabbit. Differentiation, 59: 179-192, 1995.
12. O'Brien, J. P., and Cordon-Cardo, C. P-glycoprotein expression in normal human tissues. In: S. Gupta and T. Tsuruo (eds.), Multidrug Resistance in Cancer Cells, pp. 285-291. Chichester, United Kingdom: John Wiley & Sons, 1996.
13. van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J., and Beijnen, J. H. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer, 76: 1181-1183, 1997.
14. Harrison, P. T. C. An ethanol-acetic acid-formol saline fixative for routine use with special application to the fixation of non-perfused rat lung. Lab. Anim., 18: 325-331, 1984.
15. Sparreboom, A., van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and feces by semi-automated reversed-phase high-performance liquid chromatography. J. Chromatogr., 664: 383-391, 1995.
16. van Asperen, J., Schinkel, A. H., Beijnen, J. H., Nooijen, W. J., Borst, P., and van Tellingen, O. Altered pharmacokinetics of vinblastine in mdrla P-glycoprotein-deficient mice. J. Natl. Cancer Inst. (Bethesda), 88: 994-999, 1996.
17. Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P., and Collins, J. M. Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res., 54: 4026-4035, 1994.
18. Shet, M. S., Fisher, C. W., Holmans, P. L., and Estabrook, R. W. Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc. Natl. Acad. Sci. USA, 90: 11748-11752, 1993.
19. Chan, F. K., and Shaffer, E. A. Cholestatic effects of cyclosporine in the rat. Transplantation (Baltimore), 63: 1574-1578, 1997.
20. Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., Zijlmans, J. M. J. M., Fibbe, W. E., and Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA, 94: 4028-4033, 1997.
21. Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., and Schinkel, A. H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest., 100: 2430-2436, 1997.
22. Sparreboom, A., van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res., 56: 2112-2115, 1996.
23. Kahan, B. D. Cyclosporine. N. Engl. J. Med., 321: 1725-1738, 1989.